These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 18986025)

  • 1. [Pharmacoeconomic efficiency of sparfloxacin use in empiric therapy of community-acquired pneumonia].
    Lazareva NB
    Antibiot Khimioter; 2007; 52(7-8):53-7. PubMed ID: 18986025
    [No Abstract]   [Full Text] [Related]  

  • 2. Role of gemifloxacin in community-acquired pneumonia.
    Tillotson GS
    Expert Rev Anti Infect Ther; 2008 Aug; 6(4):405-18. PubMed ID: 18662107
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The clinical and pharmacoeconomic aspects of gemifloxacin(corrected) use in the patients with extra-hospital pneumonia in stationary conditions].
    Zaĭtsev AA; Sinopal'nikova AI
    Voen Med Zh; 2007 Jan; 328(1):44-51. PubMed ID: 17436714
    [No Abstract]   [Full Text] [Related]  

  • 4. Fluoroquinolones in the management of community-acquired pneumonia.
    Albertson TE; Dean NC; El Solh AA; Gotfried MH; Kaplan C; Niederman MS
    Int J Clin Pract; 2010 Feb; 64(3):378-88. PubMed ID: 20456176
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gemifloxacin (factive).
    Med Lett Drugs Ther; 2004 Sep; 46(1192):78-9. PubMed ID: 15452464
    [No Abstract]   [Full Text] [Related]  

  • 6. Approaches to treatment of community-acquired pneumonia in the emergency department and the appropriate role of fluoroquinolones.
    Moran G
    J Emerg Med; 2006 May; 30(4):377-87. PubMed ID: 16740445
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fluoroquinolones should not be the first-line antibiotics to treat community-acquired pneumonia in areas of tuberculosis endemicity.
    Singh A
    Clin Infect Dis; 2007 Jul; 45(1):133; author reply 134-5. PubMed ID: 17554716
    [No Abstract]   [Full Text] [Related]  

  • 8. Monotherapy or combination therapy for hospitalized patients with community-acquired pneumonia: not yet the end of the story?
    Laterre PF
    Clin Infect Dis; 2008 May; 46(10):1510-2. PubMed ID: 18419483
    [No Abstract]   [Full Text] [Related]  

  • 9. [Pharmacoeconomic estimation of cost of community acquired pneumonia therapy].
    Kulidzhanov AIu; Sirotko II; Koriakin PM; Korchazhkin VS
    Voen Med Zh; 2001 Jan; 322(1):50-2. PubMed ID: 11219929
    [No Abstract]   [Full Text] [Related]  

  • 10. [Empiric therapy of community-acquired pneumonia: a transatlantic controversy].
    Garin N; Nendaz M
    Rev Med Suisse; 2006 Jan; 2(50):289-90, 292-4. PubMed ID: 16503046
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Estimation of the clinical and pharmacoeconomic efficiency of treatment in patients with community-acquired pneumonia with third-generation cephalosporins].
    Starodubtseva OI; Vakhrushev IaM
    Probl Tuberk Bolezn Legk; 2009; (6):28-9. PubMed ID: 19642570
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fluoroquinolones in the management of community-acquired pneumonia in primary care.
    Wispelwey B; Schafer KR
    Expert Rev Anti Infect Ther; 2010 Nov; 8(11):1259-71. PubMed ID: 21073291
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optimizing therapy for community-acquired pneumonia with the goal of rapid resolution of illness.
    File TM; Tan JS
    Clin Infect Dis; 2005 Dec; 41(12):1706-8. PubMed ID: 16288391
    [No Abstract]   [Full Text] [Related]  

  • 14. Fluoroquinolones in community-acquired pneumonia: guide to selection and appropriate use.
    Frei CR; Labreche MJ; Attridge RT
    Drugs; 2011 Apr; 71(6):757-70. PubMed ID: 21504252
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bacterial community-acquired pneumonia in children: changes in causative agents.
    Korppi M; Heiskanen-Kosma T
    Monaldi Arch Chest Dis; 2001 Apr; 56(2):132-6. PubMed ID: 11499302
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fluoroquinolones in community-acquired pneumonia when tuberculosis is around: an instructive case.
    Grupper M; Potasman I
    Am J Med Sci; 2008 Feb; 335(2):141-4. PubMed ID: 18277123
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sparfloxacin versus clarithromycin in the treatment of community-acquired pneumonia.
    Ramirez J; Unowsky J; Talbot GH; Zhang H; Townsend L
    Clin Ther; 1999 Jan; 21(1):103-17. PubMed ID: 10090428
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The clinical efficacy of fluoroquinolone and macrolide combination therapy compared with single-agent therapy against community-acquired pneumonia caused by Legionella pneumophila.
    Nakamura S; Yanagihara K; Izumikawa K; Seki M; Kakeya H; Yamamoto Y; Senjyu H; Saito A; Kohno S
    J Infect; 2009 Sep; 59(3):222-4. PubMed ID: 19592113
    [No Abstract]   [Full Text] [Related]  

  • 19. Health economics of use fluoroquinolones to treat patients with community-acquired pneumonia.
    Restrepo MI; Frei CR
    Am J Med; 2010 Apr; 123(4 Suppl):S39-46. PubMed ID: 20350634
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The impact of empiric antimicrobial therapy with a β-lactam and fluoroquinolone on mortality for patients hospitalized with severe pneumonia.
    Mortensen EM; Restrepo MI; Anzueto A; Pugh J
    Crit Care; 2005 Dec; 10(1):R8. PubMed ID: 16420641
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.